||EPS - Basic
||Market Cap (m)
|Health Care Equipment & Services
Bioquell Share Discussion Threads
Showing 1226 to 1250 of 1250 messages
|a bit of both I would have thought|
|Article published on the 15th so written after the options announcement but no mention of this.
Main points were cash and share buy-back.
I am pretty sure that the recent price rise was due to this article.|
|That's interesting, but surely they mentioned the point I've made above or was the IC article prior to or on 10 March (the date the share options news I mentioned above was released)? The recent rise started soon after that so I still think that that news was at the very least a contributing factor for the reason I stated above.|
|bh, I suppose you've discovered this by now but the rise was very probably due to the recent positive update in Investors Chronicle.
I sold on Friday simply because I expect the price to drift back and a 15% gain in a couple of months was more than OK.
I've been wrong before but the gain is fine even if the price doesn't come back down. If the price falls I'll almost certainly buy back in as I like the company.|
|a delayed reaction to this recent statement?
"These grants represent in aggregate approximately 4.95% of the current issued share capital and are in accordance with the rules of the PSP. The options and forfeitable shares shall vest and the options shall become exercisable on a change of control within 3 years of the date of grant at a price of more than GBP2 per share."
That's quite an incentive to the BoD to find a buyer at £2+/share!
|buybacks to continue
|header charts updated|
|I've added a couple of links to the end of the header for future reference as I'll probably forget about this within a year or so otherwise!|
|cheers, it's a bit clearer in that document:
"7. Performance conditions
Awards will not vest unless the performance conditions are satisfied. The performance condition in respect of the Initial Awards is a takeover event (or similar corporate event) in relation to the Company ("Takeover Event") satisfying one of the conditions below.
Where the Takeover Event takes place within three years of the date of grant, the condition is that the value of the consideration received by the shareholders of the Company as a result of such a transaction must equal or exceed £2 per Share;
If there is no Takeover Event within three years of the date of grant either:
• the Initial Award shall remain capable of vesting on the same basis as set out above, save that the references to "£2 per Share" shall be taken to read as "£2 per Share plus 10% per annum (calculated on a daily basis) for the period between the third anniversary of the date of grant and the date of the Takeover Event"; or
• at the discretion of the Committee, the Committee may instead set a new performance condition to be satisfied following the third anniversary of the date of grant, such new performance condition to be materially neither more difficult nor easier to satisfy than was the condition set out above as at the date of grant."
...a bid at £2 would be a 50% premium to the current share price @133p so would be a good return at any point in the next 3 yrs (and the BOD have quite an incentive!), may as well hold on to these I think, imho|
|Detail was included in the notice of the General Meeting on the BQE website.
hxxp://www.bioquellplc.com/downloads/press-releases/Bioquell_Circ_v1.pdf (see section 7).
As a general comment, BODs seem increasingly incapable of performing their function without excess rewards. I think we lesser mortals can take a bare modicum of comfort in cases such as this where there is a major shareholder who will have approved the arrangement.
Let's hope the £2 figure doesn't set a limit if there is a bid! n.b. with 5% given away a 191p bid would be preferable to a 200p bid! - does this mean an offer between 200p and 210p cannot be accepted because it would not be in shareholders best interests?!!|
|I agree with your interpretation, although the wording is poor.
Of course, a share buyback will help with that ....
And they'll be worth £2m then. Not bad for a business that made just £0.4m for its shareholders last year.|
|yes but doesn't the shareprice have to reach £2 for them to be exercisable, or a bid be received at greater than £2/share?
...surely that would indicate confidence that the share price will hit £2 within 3 years
"the options shall become exercisable on a change of control within 3 years of the date of grant at a price of more than GBP2 per share"
not crystal clear so I stand to be corrected if not the case|
The Group expects to return further cash its directors by way of nil cost shares and options during the course of 2017 in lieu of paying a dividend. Further details of this venality are announced here.http://www.investegate.co.uk/bioquell-plc--bqe-/rns/director-pdmr-shareholding/201703101018031384Z/|
|You might also want to add that the Board have just awarded themselves £1.5m worth of shares and options at no cost to themselves.
Very well deserved, I'm sure.|
|header updated replacing out of date info with...
"The Group has a strong balance sheet. GBP40.8 million of cash generated from the sale of the TRaC business in 2015 was returned to shareholders by way of a tender offer in June 2016. The Group spent a further GBP1.3 million on share buybacks in December 2016.
There was a net cash inflow before share buybacks in the second half of the year of GBP2.5 million.
Net cash at 31 December 2016 was GBP8.8 million (2015: GBP47.6 million)
The Group expects to return further cash to shareholders by way of share buybacks during the course of 2017 in lieu of paying a dividend. Further details of these buybacks will be announced in due course."|
|Has anyone got any info on what a clean 2017 is going to look like? With currency tailwind and the cash this could now be interesting if they can start to grow the volumes. Probably worth more than 1 x revenue ( ex cash ) I would have thought given the fairly high gross margins. Thanks|
|Certainly some positives in this, but there seems no coherent plan on how to use the cash (40p / share) other than to buy in a couple more million shares - that's not delivering value to most shareholders.|
|Final results out.
Ian Johnson, Executive Chairman of Bioquell PLC, said:
"I am pleased to report substantial improvements in the financial performance of the Group for 2016. Following the conclusion of the strategic review in late August 2016 we made changes to the board and restructured the Company, placing greater emphasis on building a world class bio-decontamination business. The reported improvements are in part the result of these changes, but predominantly the result of a number of other factors including lower manufacturing costs, targeted cost reduction programmes and the effect of the Brexit vote on Sterling, which given our high level of export business enhanced gross margin."
"Management continue to focus on generating top line growth from the international Life Sciences market and on improving financial performance through further efficiency initiatives and generating additional recurring revenues from the Services business."|
|Added 50% to my holdings recently and managed to buy at very slightly less than my initial purchase (see above).
Must add that the Current Ratio is (IMO) now over 4 and the EV/EBITDA figure is comfortably under 6 making this one of the best balance sheets I've seen in a long time.
The company generates a lump of cash and the cash balance is now £8.8m up from £7.3m in H1 and this after buying back £1.25m of shares in H2.
Some of this cash may come from a rebalancing of Trade payable/receivables but the EBITDA is likely to be at least £3.5m with 40p/share cash.(22m shares)
Bioquell is coming out of hibernation after the long drawn out review but very importantly it now has a new management team and although it's early days (appointed mid year)this looks a very safe bet and I suspect the new management will be putting their stamp on things as I type.|
|This looks horribly overvalued. The business is in gradual but apparently inexorable decline and, even allowing for excess cash, I value this at less than £1.
It's too overvalued to invest in and too small to short, so I'm archiving my models on this now (not that I expect anyone else to care)!
Good luck to holders.|
|some good points, especially on the market cap which will affect some of the other data quoted by advfn - I wonder how long it will take for this to be corrected|
|Couldn't resist a little punt here this morning.Got involved in BQE though the ST article and did well out of it but my initial involvement was simply based on the tender offer so sold out my second half at 145p when the sale of the remainder fell through.
Read ST's follow up piece and got the the calculator out (please note I like to read ST but only seriously consider a very small percentage of his recommendations and always do my own thing. I would never dream of blaming someone who recommended a share if that turned out to be a poor choice, it was MY CHOICE.)
BQE now looks very sound with:
1 new management
2 large and growing cash pile
3 very high Current Ratio of almost 4
4 EV/ EBITDA predicted to come in at a very low 6.5
NB ADVFN are giving the wrong market cap and it should be c. £30m not over £50m.
My calculations are based on 23m shares so please check this out if you are interested.|
|Interesting company this one. Bio- decontamination business continues to exhibit high margins but low profits and no revenue growth. Think the company has real potential but it's never really delivered. Valuation looks high at the moment, but will keep on the watch list. A buy at around a £1 with Chris Mills heavily invested I feel.|
|I got out this morning fearing a big drop
Happy to see what Simon Thompson has to say
On the face of it a uk company aiming to be a world class leader should be just the Brexit ticket
May return later|
|well well no sale and CEO goes after doing stated fine job|